Chemicals
Showing 16351–16500 of 41137 results
-
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 10 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 25 mgAvailable on backorder
D13 is an acylhydrazone antifungal.{53336} It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection.
Brand:CaymanSKU:29818 - 5 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 10 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 5 mgAvailable on backorder
D2PM (hydrochloride) is a psychoactive designer drug that has recently been demonstrated to have toxic effects in humans.{20293,20296} D2PM is also used in organic synthesis to prepare the Corey-Bakshi-Shibata catalyst.{20423} This product is intended for forensic purposes.
Brand:CaymanSKU:11160 - 50 mgAvailable on backorder
D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:- D609 is a xanthate and a competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC; Ki = 6.4 µM).{26211} It has no effect on bacterial phosphatidylinositol-specific PLC, bovine pancreatic PLA2, or phospholipase D.{26213} D609 reduces sphingomyelin synthase activity by 55.5 and 90.5% in membrane preparations when used at concentrations of 100 and 200 mg/ml, respectively.{26214} Similar to other xanthates, D609 has antioxidant, antiviral, and anti-tumor activities.{26213} In addition, it has anti-inflammatory actions, inhibiting LPS-stimulated expression of nitric oxide synthase (NOS) in phagocytes (IC50 = 20 µg/ml) and IL-1β-induced expression of vascular cell adhesion molecule 1 (VCAM-1) in endothelial cells.{26212,3364}
Brand:CaymanSKU:-
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
Cdc25 dual-specific protein tyrosine phosphatases are important for cell cycle progression and often overexpressed in cancers. Through the removal of inhibitory phosphates, they function to catalyze the activation of cyclin-Cdk complexes. DA-3003-2 is a Cdc25 phosphatase inhibitor (IC50 = 0.82 µM for human recombinant Cdc25B) that demonstrates antiproliferative activity.{17980,28275,28276} At 20 µM, it has been shown to arrest asynchronous PC-3 prostate cancer cells in G2/M phase.{28276}
Brand:CaymanSKU:-Available on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 1 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 10 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 5 mgAvailable on backorder
DAA1106 is an agonist of the 18 kDa translocator protein TSPO, which was previously known as the peripheral benzodiazepine receptor (PBR), that has an IC50 value of 0.28 nM in a radioligand binding assay.{41208} It is selective for TSPO over central benzodiazepine receptors (CBRs) and GABAA receptors in rat whole brain membranes, as well as a panel of 54 ion channels, uptake/transporters, and secondary messenger receptors at concentrations greater than 10 µM. DAA1106 increases mitochondrial prognenolone formation in rat brain homogenates, which indirectly potentiates GABAA receptor signaling. DAA1106 (1-10 mg/kg) increases the time mice spend in the light area of the light/dark exploration and the time rats spend in open arms of the elevated plus maze in a dose-dependent manner, suggesting a decrease in anxiety-like behavior. Various radiolabeled versions of DAA1106 have been synthesized to study the distribution of PBRs in neurological disease models using positron emission tomography (PET).{41209,41210}
Brand:CaymanSKU:23454 - 500 µgAvailable on backorder
Dabcyl-YVADAPV-EDANS is a fluorogenic substrate for caspase-1.{42039} Upon enzymatic cleavage by caspase-1, EDANS is separated from the Dabcyl quencher and can be used to quantify caspase-1 activity. EDANS displays excitation/emission maxima of 340/485 nm, respectively.
Brand:CaymanSKU:24993 - 1 mgAvailable on backorder
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran is a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} It also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} Dabigatran has poor bioavailability after oral administration. However, dabigatran etexilate (Item No. 17131) is a double prodrug that has excellent oral bioavailability and undergoes in vivo hydrolytic cleavage to produce dabigatran.{28063,28064}
Brand:CaymanSKU:-Out of stock
Dabigatran acyl-β-D-glucuronide is a major active metabolite of the thrombin inhibitor dabigatran (Item No. 17133). The prodrug of dabigatran, dabigatran etexilate (Item No. 17131), is hydrolyzed by plasma esterases to form dabigatran, which is metabolized primarily by the UDP-glucuronosyltransferase (UGT) isoform UGT2B15 to form dabigatran acyl-β-D-glucuronide.{28064,43581} Dabigatran acyl-β-D-glucuronide increases activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma equipotently to dabigatran.{43581}
Brand:CaymanSKU:26655 - 1 mgAvailable on backorder
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:-Out of stock
Dabrafenib-d9 is intended for use as an internal standard for the quantification of dabrafenib (Item No. 16989) by GC- or LC-MS. Dabrafenib is an ATP-competitive inhibitor of Raf kinases (IC50s = 0.64, 0.68 and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively).{42963} It also inhibits the tyrosine kinase-like kinases ALK5 and LIMK1 (IC50s = 11 and 15 nM, respectively) and the calcium/calmodulin-dependent protein kinases SIK2 and PDK2 (IC50s = 27 and 57 nM, respectively), as well as NEK11, CK1, and BRK (IC50s = 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM. Dabrafenib inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E, 133 cell lines expressing wild-type Ras and Raf, or 18 cell lines expressing mutant Ras (GI50s = >10 µM) in a panel of 195 cancer cell lines. Dabrafenib (8 nM) inhibits MAPK signaling, inhibiting phosphorylation of MEK and ERK, and activates caspase-3/7 in B-RAFV600E-expressing A375P melanoma cells but not in wild-type B-RAF-expressing human foreskin fibroblasts (EC200s =71 and >10,000 nM, respectively). It reduces tumor growth in an A375P mouse xenograft model when administered at doses ranging from 3 to 100 mg/kg. Formulations containing dabrafenib have been used in the treatment of B-RAFV600E-expressing cancers.
Brand:CaymanSKU:28797 - 1 mgAvailable on backorder
Dacarbazine-d6 is intended for use as an internal standard for the quantification of dacarbazine (Item No. 21877) by GC- or LC-MS. Dacarbazine is a DNA alkylating prodrug that is activated by P450 enzymes in liver microsomes.{21297} Following activation, it is converted, through a series of reactions, into a methyldiazonium cation that alkylates DNA at all phases of the cell cycle and induces apoptosis. In vitro, dacarbazine inhibits the growth of B16/F1, A-875, and SK-MEL-5 melanoma and non-cancerous WI-38 lung fibroblast and L-02 hepatocyte cell lines (IC50s = 260, 287, 380, 526, and 367 μM, respectively).{41584} Dacarbazine toxicity to 518A2 and SK-MEL-28 melanoma cell lines increases in a time-dependent manner with IC50 values of 121 and >400 μM, respectively, following a 1 hour incubation and 2.5 and 50 μM, respectively, following a 96 hour incubation.{41585} In vivo, dacarbazine (70 mg/kg, once every 2 days) decreases tumor volume by 59.1% in a B16/F1 murine melanoma model in mice.{41584} Formulations containing dacarbazine have been used in the treatment of metastatic melanoma and for Hodgkin’s lymphoma in combination with other antineoplastic agents.
Brand:CaymanSKU:30771 - 1 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 10 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 25 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 5 mgAvailable on backorder
Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:23730 - 50 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 1 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 5 mgAvailable on backorder
Daclatasvir-d6 is intended for use as an internal standard for the quantification of daclatasvir (Item No. 23730) by GC- or LC-MS. Daclatasvir is a first generation direct-acting inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A; Kds = 8 and 210 nM for the NS5A33-202 and NS5A26-202 residues of HCV genotype 1b, respectively).{36292,36293} It potently inhibits HCV replication in multiple HCV replicon genotypes (EC50s = 9-146 pM) with the highest potency in genotypes 1b and 4a (EC50s = 9 and 12 pM, respectively).{36292} Daclatasvir disrupts the subcellular localization of NS5A in Huh7.5 cells and inhibits viral RNA synthesis and virion assembly and secretion when used at a concentration of 1 nM in HCV-infected Huh7 cells.{36294,36295} Daclatasvir also inhibits organic anion transport polypeptides 1B1 (OAT1B1) and OAT1B3 (IC50s = 1.5 and 3.27 µM, respectively).{36296} Formulations containing daclatasvir have been used alone and in combination with NS3/4A and NS5B inhibitors in the treatment of HCV.
Brand:CaymanSKU:29077 - 500 µgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 1 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 10 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 5 mgAvailable on backorder
DADLE is a peptide agonist of δ-opioid receptors (Ki = 2.06 nM in a radioligand binding assay).{37712} It is selective for δ-opioid over κ-opioid receptors (Ki = 16,000 nM) but also agonizes μ-opioid receptors (Ki = 13.8 nM). DADLE inhibits electrically induced contractions in guinea pig myenteric plexus and mouse and rat vas deferens (IC50s = 8.9, 0.73, and 134 nM, respectively). It induces analgesia in the tail-flick and hot plate tests in mice (ED50s = 0.03 and 0.027 nmol per animal, i.c.v.).{52196} DADLE (2.5 mg/kg) decreases infarct volume in a rat model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO).{52197}
Brand:CaymanSKU:28928 - 50 mgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 1 mgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 100 µgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 250 µgAvailable on backorder
DAF-2 is a sensitive fluorescent indicator commonly used for the detection of nitric oxide (NO).{6360,6632} It reacts with NO in the presence of oxygen to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nM, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM.
Brand:CaymanSKU:85160 - 500 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 1 mgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 100 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 250 µgAvailable on backorder
DAF-2 diacetate is a sensitive fluorescent indicator for the detection and bioimaging of nitric oxide (NO).{6360,6632} It is a cell-permeable derivative of DAF-2. Upon entry into the cell, DAF-2 diacetate is transformed into the less cell-permeable DAF-2 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. In the presence of oxygen, DAF-2 reacts with NO to yield the highly fluorescent triazolofluorescein (DAF-2T). Fluorescence is monitored using excitation and emission wavelengths of 485 and 538 nm, respectively.{6632} At neutral pH the detection limit for NO is 2-5 nM. DAF-2 diacetate can be utilized in cells which produce small amounts of NO, such as endothelial cells, as well as in cells which generate large amount of NO, such as macrophages.{6360,6632}
Brand:CaymanSKU:85165 - 500 µgAvailable on backorder
DAF-FM diacetate is a cell-permeable, fluorescent probe for the detection and bioimaging of nitric oxide (NO) with excitation/emission maxima of 495/515 nm. It passively diffuses across cellular membranes and, once inside cells, is deacetylated by intracellular esterases to become DAF-FM. The fluorescence quantum yield of DAF-FM is ~0.005, but increases about 160-fold, to ~0.81, after reacting with NO.{30226} DAF-FM is advantageous over the NO probe, DAF-2 (Item No. 85160) for several reasons: 1) the spectra of the NO adduct of DAF-FM are independent of pH above pH 5.5; 2) the NO adduct of DAF-FM is significantly more photostable than that of DAF-2; 3) the NO detection limit of DAF-FM (~3 nM) is more sensitive than that of DAF-2 (~5 nM).{30226,30225}
Brand:CaymanSKU:-Available on backorder
DAF-FM diacetate is a cell-permeable, fluorescent probe for the detection and bioimaging of nitric oxide (NO) with excitation/emission maxima of 495/515 nm. It passively diffuses across cellular membranes and, once inside cells, is deacetylated by intracellular esterases to become DAF-FM. The fluorescence quantum yield of DAF-FM is ~0.005, but increases about 160-fold, to ~0.81, after reacting with NO.{30226} DAF-FM is advantageous over the NO probe, DAF-2 (Item No. 85160) for several reasons: 1) the spectra of the NO adduct of DAF-FM are independent of pH above pH 5.5; 2) the NO adduct of DAF-FM is significantly more photostable than that of DAF-2; 3) the NO detection limit of DAF-FM (~3 nM) is more sensitive than that of DAF-2 (~5 nM).{30226,30225}
Brand:CaymanSKU:-Available on backorder
Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:10005166 - 1 gAvailable on backorder
Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:10005166 - 100 mgAvailable on backorder
Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:10005166 - 5 gAvailable on backorder
Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:10005166 - 500 mgAvailable on backorder
Daidzein-d4 is intended for use as an internal standard for the quantification of daidzein (Item No. 10005166) by GC- or LC-MS. Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:-Available on backorder
Daidzein-d4 is intended for use as an internal standard for the quantification of daidzein (Item No. 10005166) by GC- or LC-MS. Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:-Available on backorder
Daidzein-d4 is intended for use as an internal standard for the quantification of daidzein (Item No. 10005166) by GC- or LC-MS. Daidzein is an isoflavone phytoestrogenic compound that has been found in soybeans and other legumes.{42157} It binds to estrogen receptor β (ERβ; Ki = 2.8 µM) but not ERα at concentrations up to 1 mM.{42156} It is estrogenic in vitro, increasing gene transcription mediated by the estrogen response element (ERE) in a reporter assay in an ERβ-dependent manner (EC50 = 2.8 µM for MCF-7 cells expressing ERβ).{42157} Daidzein is an inhibitor of carbonic anhydrase (CA) that is selective for carbonic CAVII and CAXII (Kis = 4.2 and 56 nM, respectively) over CAI, II, and IV (Kis = >10,000, >10,000, and 718.7 nM, respectively).{42158} It reduces tumor growth in a PC3 prostate cancer mouse orthotopic model when administered at a dose of 50 mg/kg per day and potentiates the effects of radiation therapy.{42159}
Brand:CaymanSKU:-Available on backorder
Daidzin is an isoflavone that occurs naturally in some plants, including soy and kudzu root. Like other isoflavones, daidzin has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.{19709} Daidzin directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.{16840,19708}
Brand:CaymanSKU:- Daidzin is an isoflavone that occurs naturally in some plants, including soy and kudzu root. Like other isoflavones, daidzin has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.{19709} Daidzin directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.{16840,19708}
Brand:CaymanSKU:- Daidzin is an isoflavone that occurs naturally in some plants, including soy and kudzu root. Like other isoflavones, daidzin has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.{19709} Daidzin directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.{16840,19708}
Brand:CaymanSKU:- Daidzin is an isoflavone that occurs naturally in some plants, including soy and kudzu root. Like other isoflavones, daidzin has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities.{19709} Daidzin directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.{16840,19708}
Brand:CaymanSKU:-
Dalbavancin is a semisynthetic glycopeptide antibiotic.{45081} It inhibits the growth of Gram-positive bacteria in vitro, including S. pneumoniae, S. pyogenes, vancomycin-sensitive Enterococcus species, and various methicillin-resistant staphylococci (MIC50s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with S. aureus and S. pneumoniae (ED50s = 0.08 and 0.56 mg/kg, respectively). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.
Brand:CaymanSKU:21161 -Out of stock
Dalbavancin is a semisynthetic glycopeptide antibiotic.{45081} It inhibits the growth of Gram-positive bacteria in vitro, including S. pneumoniae, S. pyogenes, vancomycin-sensitive Enterococcus species, and various methicillin-resistant staphylococci (MIC50s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with S. aureus and S. pneumoniae (ED50s = 0.08 and 0.56 mg/kg, respectively). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.
Brand:CaymanSKU:21161 -Out of stock
Dalbavancin is a semisynthetic glycopeptide antibiotic.{45081} It inhibits the growth of Gram-positive bacteria in vitro, including S. pneumoniae, S. pyogenes, vancomycin-sensitive Enterococcus species, and various methicillin-resistant staphylococci (MIC50s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with S. aureus and S. pneumoniae (ED50s = 0.08 and 0.56 mg/kg, respectively). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.
Brand:CaymanSKU:21161 -Out of stock
Dalbavancin is a semisynthetic glycopeptide antibiotic.{45081} It inhibits the growth of Gram-positive bacteria in vitro, including S. pneumoniae, S. pyogenes, vancomycin-sensitive Enterococcus species, and various methicillin-resistant staphylococci (MIC50s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with S. aureus and S. pneumoniae (ED50s = 0.08 and 0.56 mg/kg, respectively). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.
Brand:CaymanSKU:21161 -Out of stock
Cholesteryl ester transfer protein (CETP) is an exchange protein which transfers cholesteryl esters from HDL to VLDL, IDL, and LDL in exchange for triglycerides.{11793,15303} Dalcetrapib is an inhibitor of CETP that exhibits an IC50 value of 9 µM for plasma CETP in rabbits.{8320} Inhibition of CETP by dalcetrapib in rabbits given an atherogenic diet leads to elevation of HDL, decreased VLDL, and attenuation of the induced atherosclerosis.{8320} In human subjects, dalcetrapib also inhibits CETP activity and increases plasma HDL levels but it does not reduce the risk of recurrent cardiovascular events.{15303,21933}
Brand:CaymanSKU:89450 - 1 mgAvailable on backorder
Cholesteryl ester transfer protein (CETP) is an exchange protein which transfers cholesteryl esters from HDL to VLDL, IDL, and LDL in exchange for triglycerides.{11793,15303} Dalcetrapib is an inhibitor of CETP that exhibits an IC50 value of 9 µM for plasma CETP in rabbits.{8320} Inhibition of CETP by dalcetrapib in rabbits given an atherogenic diet leads to elevation of HDL, decreased VLDL, and attenuation of the induced atherosclerosis.{8320} In human subjects, dalcetrapib also inhibits CETP activity and increases plasma HDL levels but it does not reduce the risk of recurrent cardiovascular events.{15303,21933}
Brand:CaymanSKU:89450 - 10 mgAvailable on backorder
Cholesteryl ester transfer protein (CETP) is an exchange protein which transfers cholesteryl esters from HDL to VLDL, IDL, and LDL in exchange for triglycerides.{11793,15303} Dalcetrapib is an inhibitor of CETP that exhibits an IC50 value of 9 µM for plasma CETP in rabbits.{8320} Inhibition of CETP by dalcetrapib in rabbits given an atherogenic diet leads to elevation of HDL, decreased VLDL, and attenuation of the induced atherosclerosis.{8320} In human subjects, dalcetrapib also inhibits CETP activity and increases plasma HDL levels but it does not reduce the risk of recurrent cardiovascular events.{15303,21933}
Brand:CaymanSKU:89450 - 5 mgAvailable on backorder
Cholesteryl ester transfer protein (CETP) is an exchange protein which transfers cholesteryl esters from HDL to VLDL, IDL, and LDL in exchange for triglycerides.{11793,15303} Dalcetrapib is an inhibitor of CETP that exhibits an IC50 value of 9 µM for plasma CETP in rabbits.{8320} Inhibition of CETP by dalcetrapib in rabbits given an atherogenic diet leads to elevation of HDL, decreased VLDL, and attenuation of the induced atherosclerosis.{8320} In human subjects, dalcetrapib also inhibits CETP activity and increases plasma HDL levels but it does not reduce the risk of recurrent cardiovascular events.{15303,21933}
Brand:CaymanSKU:89450 - 50 mgAvailable on backorder
Brand:CaymanSKU:29501 - 1 mgAvailable on backorder
Daminozide is a highly selective inhibitor of the human 2-oxoglutarate (JmjC) histone demethylases KDM2A, PHF8, and KDM7A with IC50 values of 1.5, 0.55, and 2.1 μM, respectively.{21348} When tested for inhibition of other demethylase subfamily members (KDM3, KDM4, KDM5, KDM6) and other 2OG oxygenases (FIH, PHD2, BBOX1), daminozide was considerably less potent (IC50s > 100 μM).{21348} Daminozide is known to retard plant growth and was widely used in the 1960s for agricultural and horticultural applications to control plant size and fruit ripening before it was withdrawn because of carcinogenicity concerns.{21397}
Brand:CaymanSKU:12033 - 10 gAvailable on backorder
Daminozide is a highly selective inhibitor of the human 2-oxoglutarate (JmjC) histone demethylases KDM2A, PHF8, and KDM7A with IC50 values of 1.5, 0.55, and 2.1 μM, respectively.{21348} When tested for inhibition of other demethylase subfamily members (KDM3, KDM4, KDM5, KDM6) and other 2OG oxygenases (FIH, PHD2, BBOX1), daminozide was considerably less potent (IC50s > 100 μM).{21348} Daminozide is known to retard plant growth and was widely used in the 1960s for agricultural and horticultural applications to control plant size and fruit ripening before it was withdrawn because of carcinogenicity concerns.{21397}
Brand:CaymanSKU:12033 - 25 gAvailable on backorder
Daminozide is a highly selective inhibitor of the human 2-oxoglutarate (JmjC) histone demethylases KDM2A, PHF8, and KDM7A with IC50 values of 1.5, 0.55, and 2.1 μM, respectively.{21348} When tested for inhibition of other demethylase subfamily members (KDM3, KDM4, KDM5, KDM6) and other 2OG oxygenases (FIH, PHD2, BBOX1), daminozide was considerably less potent (IC50s > 100 μM).{21348} Daminozide is known to retard plant growth and was widely used in the 1960s for agricultural and horticultural applications to control plant size and fruit ripening before it was withdrawn because of carcinogenicity concerns.{21397}
Brand:CaymanSKU:12033 - 5 gAvailable on backorder
DAN-1 EE is a fluorescent indicator for the bioimaging of nitric oxide (NO).{6534} DAN-1 EE is a cell permeable derivative of DAN, a molecule which has been used extensively in the quantitation of nitrate and nitrite using fluorescence spectroscopy.{2762,1701} Upon entry into the cell, DAN-1 EE is transformed into the less cell permeable DAN-1 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. Intracellular formation of NO can be monitored using excitation and emission wavelengths of 360-380 nm and 420-450 nm, respectively.{6534}
Brand:CaymanSKU:85070 - 1 mgAvailable on backorder
DAN-1 EE is a fluorescent indicator for the bioimaging of nitric oxide (NO).{6534} DAN-1 EE is a cell permeable derivative of DAN, a molecule which has been used extensively in the quantitation of nitrate and nitrite using fluorescence spectroscopy.{2762,1701} Upon entry into the cell, DAN-1 EE is transformed into the less cell permeable DAN-1 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. Intracellular formation of NO can be monitored using excitation and emission wavelengths of 360-380 nm and 420-450 nm, respectively.{6534}
Brand:CaymanSKU:85070 - 10 mgAvailable on backorder
DAN-1 EE is a fluorescent indicator for the bioimaging of nitric oxide (NO).{6534} DAN-1 EE is a cell permeable derivative of DAN, a molecule which has been used extensively in the quantitation of nitrate and nitrite using fluorescence spectroscopy.{2762,1701} Upon entry into the cell, DAN-1 EE is transformed into the less cell permeable DAN-1 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. Intracellular formation of NO can be monitored using excitation and emission wavelengths of 360-380 nm and 420-450 nm, respectively.{6534}
Brand:CaymanSKU:85070 - 5 mgAvailable on backorder
DAN-1 EE is a fluorescent indicator for the bioimaging of nitric oxide (NO).{6534} DAN-1 EE is a cell permeable derivative of DAN, a molecule which has been used extensively in the quantitation of nitrate and nitrite using fluorescence spectroscopy.{2762,1701} Upon entry into the cell, DAN-1 EE is transformed into the less cell permeable DAN-1 by cellular esterases thus preventing loss of signal due to diffusion of the molecule from the cell. Intracellular formation of NO can be monitored using excitation and emission wavelengths of 360-380 nm and 420-450 nm, respectively.{6534}
Brand:CaymanSKU:85070 - 50 mgAvailable on backorder